|
Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally-selective opioid antagonist developed by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation.〔(【引用サイトリンク】 Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119 )〕 It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia. Chemically, naloxegol is a pegylated derivative of naloxol. The pegylation prevents the drug from crossing the blood-brain barrier.〔 Naloxegol was previously a schedule II drug because of its chemical similarity to opium alkaloids. It was recently reclassified as a prescription drug after the FDA concluded that it was not habit-forming and lacked abuse potential as it does not cross the blood brain barrier. == See also == * Alvimopan * Naldemedine 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Naloxegol」の詳細全文を読む スポンサード リンク
|